Julia Souvorova
Foot Surgery · Chula Vista, CANPI 1114361029
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $372 of the $505 with a category attached, or 73.7%. 7 manufacturers reported payments, led by Integra Lifesciences Corporation at 38.7% of the total. That places this record below the midpoint for foot surgery clinicians in CA, where the typical reported total is $733.
Across 17 payments — averaging $29.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Integra Lifesciences Corporation$196
- Smith+Nephew$104
- Stryker$82
- Zimmer Biomet$79
- Assertio Therapeutics, Inc.$20
- Merck$17
- plus $7 from 1 others
What the payments were for
- Food & beverage$37274%
- Other$13326%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Integra Lifesciences Corporation | 3 | $196 |
| Smith+Nephew | 6 | $104 |
| Stryker | 3 | $82 |
| Zimmer Biomet | 2 | $79 |
| Assertio Therapeutics, Inc. | 1 | $20 |
| Merck | 1 | $17 |
| Biowound Solutions, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MICROMATRIX$133
How this compares
$505 in reported general payments places this provider in the 40th percentile of 71 foot surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketoconazole | 159 | $5,156 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 95 | $554 |
| Doxycycline Hyclate | 14 | $129 |
| Diclofenac Sodium | 11 | $122 |
| Ciprofloxacin Hcl | 27 | $113 |
| Ibuprofen | 17 | $54 |
| Clindamycin Hcl | 13 | $43 |
| Cephalexin | 15 | $38 |
Paid to pharmacies, not to this prescriber.
Other foot surgery in Chula Vista
- David MazzaChula Vista$425
- Alexander ReyzelmanSan Francisco$137K
- Helen ShnolBeverly Hills$22K
- Benedict ChingFountain Valley$19K
- Zachary KramerEncinitas$14K
- Tara HarringtonElk Grove$12K
- Jack MorganMonterey Park$11K
- Jaehyun KimSunnyvale$7K
- Ingrid EdelmanSan Diego$6K
- Spencer SterlingBellflower$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.